| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 03/15/2007 | US20070060504 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections |
| 03/15/2007 | US20070060503 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections |
| 03/15/2007 | US20070060502 Substituted propane phosphinic acid derivatives |
| 03/15/2007 | US20070060501 Methods and therapies for potentiating a therapeutic action of an opioid receptor agonist and inhibiting and/or reversing tolerance to opioid receptor agonists |
| 03/15/2007 | US20070060500 Pharmaceutical compositions for prevention of overdose or abuse |
| 03/15/2007 | US20070060499 Chloroquine combination drugs and methods for their synthesis |
| 03/15/2007 | US20070060498 2' and 3'-Prodrugs of 1', 2', 3' or 4'-branched beta -D or beta -L nucleosides provide superior results against flaviviruses and pestiviruses, including hepatitis C virus and viruses that replicate through an RNA dependent RNA reverse transcriptase; administering interferons as second antivirus agent |
| 03/15/2007 | US20070060497 Reagents for modifying biopharmaceuticals, the use and production thereof |
| 03/15/2007 | US20070059829 Invention relates to finding that Cristin/R-spondin family of heparin-binding proteins function as Fzd8/LRP6 receptors and induce beta -catenin/TCF-dependent gene activation via Wnt signaling pathway, instrumental in regulation of cell proliferation, differentiation and morphogenesis |
| 03/15/2007 | US20070059825 Cytokine zalpha11 ligand antibodies |
| 03/15/2007 | US20070059804 polynucleotides that code cysteine mutant proteins that bind to their cognate receptor or exhibit antiviral activity |
| 03/15/2007 | US20070059803 Mammalian cytokines; related reagents and methods |
| 03/15/2007 | US20070059799 Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions |
| 03/15/2007 | US20070059798 Polypeptides useful for molecular weight determinations |
| 03/15/2007 | US20070059797 genetic enhancers comprising the nucleotide sequences that elevates transcription of a heterologous coding sequence in a host cell |
| 03/15/2007 | US20070059796 Binding motif and methods of regulating cell function |
| 03/15/2007 | US20070059794 Chaperonin-target protein complex, method of producing the same, method of stabilizing target protein, method of immobilizing target protein, method of analyzing the structure of target protein, sustained-release formulation, and method of producing antibody against target protein |
| 03/15/2007 | US20070059793 Nogo receptor binding protein |
| 03/15/2007 | US20070059772 Phosphorylated glyoxalase I and its use |
| 03/15/2007 | US20070059758 Regulators of type-1 tumor necrosis factor receptor and other cytokine receptor shedding |
| 03/15/2007 | US20070059756 Immunointeractive molecules and their uses in treating subjects suffering from Hev b 5 allergies |
| 03/15/2007 | US20070059738 Administering to host a therapeutically effective amount of an agent which prevents the interaction of mucosal addressin cell adhesion molecule-1 with a ligand therefor |
| 03/15/2007 | US20070059730 Novel 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 and 49933 molecules and uses therefor |
| 03/15/2007 | US20070059729 Nucleic acids and corresponding proteins entitled 282P1G3 useful in treatment and detection of cancer |
| 03/15/2007 | US20070059724 Novel compositions and methods for lymphoma and leukemia |
| 03/15/2007 | US20070059723 Diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with Secs-1 polypeptides |
| 03/15/2007 | US20070059691 Method for determining the susceptibility of a subject to infection |
| 03/15/2007 | US20070059689 Hybrid glycosylated products and their production and use |
| 03/15/2007 | US20070059684 Method of identifying an antiviral agent |
| 03/15/2007 | US20070059681 Method for production of bioresorable microparticles, microparticles thus obtained and use thereof |
| 03/15/2007 | US20070059383 Therapeutic composition and method of supporting the immune system |
| 03/15/2007 | US20070059376 Peptide conjugate |
| 03/15/2007 | US20070059374 Method of Drug Formulation Based on Increasing the Affinity of Active Agents for Crystalline Microparticle Surfaces |
| 03/15/2007 | US20070059373 Method of Drug Formulation Based on Increasing the affinity of Crystalline Microparticle Surfaces for Active Agents |
| 03/15/2007 | US20070059363 Continuously introducing the mixed fluids into a dryer from the two or more different fluids for preparation of sustained release microspheres containing a biodegradable polymer, a drug, an additive and a solvent with different types of contents or both of the components, by controlling the mixing ratios |
| 03/15/2007 | US20070059338 Compositions and techniques for localized therapy |
| 03/15/2007 | US20070059336 Anti-angiogenic sustained release intraocular implants and related methods |
| 03/15/2007 | US20070059321 Methods of reducing minimal inhibitory concentration of antibiotics and compositions resulting therefrom |
| 03/15/2007 | US20070059320 Method for ameliorating pain by modification of NMDA receptors through inhibition of Src |
| 03/15/2007 | US20070059316 Singlet oxygen photosensitizers activated by target binding enhancing the selectivity of targeted pdt agents |
| 03/15/2007 | US20070059314 Novel anti-angiogenic agent and its use in particular within the framework of the treatment of cancer |
| 03/15/2007 | US20070059313 Homogeneous preparations of il-28 and il-29 |
| 03/15/2007 | US20070059308 efficient, high throughput screening of antibody libraries against proteins targets; for screening a diverse antibody library for antibodies that bind to a membrane protein such as a chemokine receptor in yeast |
| 03/15/2007 | US20070059307 Biological products |
| 03/15/2007 | US20070059303 monoclonal antibody for prevention and treatment of allergies, asthma, crohn's and lymes disease, arthritis, diabetes, glomerularnephritis, vision defects, skin disorders, sarcoidosis and viral diseases |
| 03/15/2007 | US20070059300 Compounds and compositions to control abnormal cell growth |
| 03/15/2007 | US20070059299 S-adenosyl methionine decarboxylase inhibition for the treatment of a herpes simplex virus infection |
| 03/15/2007 | US20070059294 Therapeutiv preparation for hematopoietic disease |
| 03/15/2007 | US20070059290 Transcriptional regulation of target genes |
| 03/15/2007 | US20070059289 Methods of improving cardiac function and attenuating and/or preventing cardiac remodeling with Hsp20 |
| 03/15/2007 | US20070059288 Treatment for heart disease |
| 03/15/2007 | US20070059287 Modified tert promoter with enhanced tumor-specificity and strength and recombinant vector comprising the same |
| 03/15/2007 | US20070059285 Human serum albumin-free stabilized interferon liquid formulations |
| 03/15/2007 | US20070059284 Methods of treating infections using il-21 |
| 03/15/2007 | US20070059283 Feline IL-18 nucleic acid molecules |
| 03/15/2007 | US20070059282 Immunocytokine sequences and uses thereof |
| 03/15/2007 | US20070059281 Composite bone graft substitute cement and articles produced therefrom |
| 03/15/2007 | US20070059280 Inhibitors of colony stimulating factors |
| 03/15/2007 | US20070059279 Pharmaceutical composition for preventing or treating malignant glioma |
| 03/15/2007 | US20070059252 follicle stimulating hormone (FSH) and luteinising hormone (LH); surfactant such as polyoxyethylene sorbitan monolaurate, polyoxyethylene sorbitan monopalmitate, and polyoxyethylene sorbitan monooleate, and stabilizer and tonicity agent such as monosaccharides, disaccharides and sugar alcohols |
| 03/15/2007 | US20070059241 neutralizing monoclonal antibodies against human Insulin-like Growth Factor Receptor-I (IGFR1); anticancer agent |
| 03/15/2007 | CA2812110A1 Targeted identification of immunogenic peptides |
| 03/15/2007 | CA2643205A1 Agent for correcting stress-inducing neuro-mediator, neuro- endocrine and metabolic disturbances and method for preventing and treating concomitant pathological conditions |
| 03/15/2007 | CA2641386A1 Endothelin receptors in morphine withdrawal |
| 03/15/2007 | CA2640796A1 Milk derived composition and use to enhance muscle mass or muscle strength |
| 03/15/2007 | CA2623412A1 Analogs of gastric inhibitory polypeptide as a treatment for age related decreased pancreatic beta cell function |
| 03/15/2007 | CA2622069A1 Treatment of diabetes related obesity |
| 03/15/2007 | CA2622016A1 Interferon lambda therapy for treatment of respiratory diseases |
| 03/15/2007 | CA2621973A1 Chimeric hcn channels |
| 03/15/2007 | CA2621767A1 Prion-specific peptoid reagents |
| 03/15/2007 | CA2621739A1 Composition of whey growth factor extract for reducing muscle inflammation |
| 03/15/2007 | CA2621699A1 Stabilized glp-1 analogs |
| 03/15/2007 | CA2621697A1 Method of treating myasthenia gravis comprising a ev576 or omcl protein |
| 03/15/2007 | CA2621577A1 Methods and compositions for oral administration of proteins |
| 03/15/2007 | CA2621560A1 Modulation of neurogenesis by hdac inhibition |
| 03/15/2007 | CA2621539A1 Methods for treating immune mediated neurological diseases |
| 03/15/2007 | CA2621482A1 Lopap-based pharmaceutical compositions and uses thereof |
| 03/15/2007 | CA2621414A1 Mmp-7 and adf derived tumour-associated peptides binding to human leukocyte antigen (hla) class i or ii molecules |
| 03/15/2007 | CA2621272A1 Anchoring disruption molecules |
| 03/15/2007 | CA2620633A1 Modified biodegradable polymers, preparation and use thereof for making biomaterials and dressings |
| 03/15/2007 | CA2620156A1 Method of treating glaucoma |
| 03/15/2007 | CA2603102A1 Elastin protective polyphenolics and methods of using the same |
| 03/14/2007 | EP1762623A1 Methods for producing biologically active peptide dimers |
| 03/14/2007 | EP1762620A2 Cryptosporidium parvum antigens, antibodies thereto and diagnostic and therapeutic compositions thereof |
| 03/14/2007 | EP1762619A2 Multiple-tumor aberrant growth genes |
| 03/14/2007 | EP1762617A1 Method for manufacturing recombinant polyclonal proteins |
| 03/14/2007 | EP1762610A1 Truncated dance, dance complex and method of using these |
| 03/14/2007 | EP1762574A2 Chemical modification of proteins to improve biocompatibility and bioactivity |
| 03/14/2007 | EP1762248A1 Use of cobalt porphyrins in joint therapy with an immunosuppressant drug for treatment of transplant patients or autoimmune disorders |
| 03/14/2007 | EP1762247A1 The use of anabolic agents, anti-catabolic agents, antioxidant agents, and analgesics for protection, treatment and repair of connective tissue in humans and animals |
| 03/14/2007 | EP1762244A1 Bmp-9 compositions for inducing differentiation of cholinergic neurons |
| 03/14/2007 | EP1762243A1 Factor for regulation of neurite growth |
| 03/14/2007 | EP1762242A1 MALIGNANT TUMOR INHIBITOR CONTAINING Des A FIBRIN |
| 03/14/2007 | EP1762236A2 Formulations of alpha adrenergic receptor antagonists and their uses |
| 03/14/2007 | EP1761784A2 Identification of ergothioneine transporter and therapeutic uses thereof |
| 03/14/2007 | EP1761630A2 Glycosylation-disrupted factor vii variants |
| 03/14/2007 | EP1761560A1 Peptide-based compounds |
| 03/14/2007 | EP1761553A2 Tumor-associated peptides that bind to mhc-molecules |
| 03/14/2007 | EP1761274A1 Use of factor viia or factor viia equivalents for preventing or attentuating haemorrhage growth, and/or oedema generation following intracerebral haemorrhage (ich) |
| 03/14/2007 | EP1761273A1 Treatment of non alcoholic steatotic hepatitis (nash) |